Director, Cath Lab and Intervention Cardiovascular Institute Mount Sinai Medical Center, New York, New York E-mail: Samin.Sharma@mountsinai.org Primary percutaneous coronary intervention (PCI) using stents (bare-metal or drug-eluting) has become the gold standard of treatment of ST-segment elevation myocardial infarction (STEMI). Numerous studies have established the importance of shortening the door-to-balloon time to
1. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: A report of the ACC/AHA Task Force on Practice Guidelines. Circulation 2008;117:296‚Äì329.
2. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006‚Äì1017.
3. Keely EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13‚Äì20.
4. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004;109:1704‚Äì1706.